Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

NCT05673811 is registered in ClinicalTrials.gov with Theriva Biologics SL as lead sponsor.

NCT NCT05673811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05673811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
Lead sponsor
Theriva Biologics SL
Phase
Phase 2
Overall status
Completed
Start date
January 10, 2023
Completion date
March 28, 2025
Enrollment
112 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic, pancreatic adenocarcinoma